Effect of baseline and changes in systolic blood pres- sure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail. 2008;1:34 42. doi: 10.1161/ CIRCHEARTFAILURE.107.736975. 61. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archam- bault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on the effectiveness of a fixed-dose combina- tion of isosorbide dinitrate and hydralazine in the African-Ameri- can Heart Failure Trial. J Am Coll Cardiol. 2007;49:32 39. doi: 10.1016/j.jacc.2006.04.109. 62. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart fail- ure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004;43:1423 1429. doi: 10.1016/j.jacc.2003.11.037. 63. Effect of enalapril on survival in patients with reduced left ven- tricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991;325:293 302. 64. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a ran- domised trial. Lancet. 1999;353:9 13. 65. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349 1355. doi: 10.1056/NEJM199605233342101. 66. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 1658. doi: 10.1056/NEJM200105313442201. 67. 